检查点抑制在局限性膀胱癌中的作用
本文系统综述了2000年1月至2017年12月MEDLINE数据库中关于检查点抑制剂(CPI)在局限性膀胱癌(非肌层浸润性或肌层浸润性)中应用的临床前与临床证据。临床前模型和回顾性分析支持CPI在局限性尿路上皮癌中的概念验证,前瞻性试点试验显示适应性免疫应答增强,多项临床试验正在进行。结论认为现有证据足以支持在前瞻性临床试验中研究CPI方案。
要点
- CPI已是转移性膀胱癌的标准治疗选择,但在早期局限性膀胱癌中的作用尚未明确。
- 临床前免疫健全小鼠、啮齿动物和犬模型均支持CPI在局限性尿路上皮癌中的概念验证。
- 回顾性分析证实部分局限性尿路上皮癌肿瘤样本存在PD-1、PD-L1或CTLA-4。
核心结论
- 来自临床前模型及局限性尿路上皮癌和转移性尿路上皮癌患者的回顾性数据足以支持在前瞻性临床试验中研究CPI方案。
研究设计与样本
- 系统综述,检索MEDLINE数据库,检索词包括膀胱癌、尿路上皮癌、移行细胞、局限性、肌层浸润性、非肌层浸润性、表浅、PD-1、PD-L1、CTLA-4和检查点抑制剂(单独及组合使用)。
- 检索限制为2000年1月至2017年12月间的出版物,并纳入近期会议公开的相关摘要。
主要发现
- 临床前免疫健全小鼠、啮齿动物和犬模型均显示CPI治疗局限性尿路上皮癌的概念验证支持。
- 对局限性尿路上皮癌肿瘤样本的回顾性分析证实部分患者存在PD-1、PD-L1或CTLA-4。
- 局限性尿路上皮癌中CPI治疗的前瞻性试点试验显示适应性免疫应答指标增强。
- 改进的全转录组平台可能进一步优化CPI治疗的患者选择。
- 多项局限性尿路上皮癌的CPI治疗临床试验正在进行,具有重大改变实践的潜力。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Checkpoint inhibitors (CPIs) are established as a standard therapy option for metastatic bladder cancer; however, their role in earlier-stage disease remains undefined. OBJECTIVE: To summarize the preclinical and clinical evidence forming the rationale for multiple ongoing investigations of CPIs in patients with localized bladder cancer defined by non-muscle-invasive or muscle-invasive stages. EVIDENCE ACQUISITION: A systematic review of the literature in the MEDLINE database was performed. The central search strategy used the terms bladder cancer, urothelial carcinoma, transitional cell, localized, muscle-invasive, non-muscle-invasive, superficial, PD-1, PD-L1, CTLA-4, and checkpoint inhibitor, both alone and in combination. The search was limited to publications between January 2000 and December 2017. Publicly available relevant abstracts from recent meetings were also included. EVIDENCE SYNTHESIS: Preclinical immunocompetent murine, rodent, and canine models have each demonstrated proof-of-concept support for CPI therapy approaches in localized urothelial carcinoma (UC). Retrospective analysis of localized UC tumor samples confirms the presence of PD-1, PD-L1, or CTLA-4 in a proportion of patients. Prospective pilot trials of CPI therapy in localized UC demonstrated enhanced adaptive immune response measures. Improved whole-transcriptome platforms may further refine patient selection for CPI therapy. Multiple clinical trials of CPI therapy in localized UC are under way with significant practice-changing potential. CONCLUSIONS: Evidence from preclinical models and retrospective data for patients with localized UC and metastatic UC sufficiently justifies the investigation of CPI approaches in the context of prospective clinical trials. PATIENT SUMMARY: Checkpoint inhibitor (CPI) therapy has provided durable tumor control in a small portion of patients with metastatic urothelial carcinoma (UC). Investigating the potential for similar sustained tumor control in localized UC is logical. Ongoing prospective clinical trials will define whether or not CPI therapy should be extended to patients with curable localized UC in whom standards for successful clinical outcomes are higher and acceptance rates of severe treatment-related toxicity are lower.
引用
- Hahn NM, Necchi A, Loriot Y, et al. Role of Checkpoint Inhibition in Localized Bladder Cancer. Eur Urol Oncol. 2018. PMID: 31102620. doi:10.1016/j.euo.2018.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。